美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Pharmaceuticals ETF

68.47

+0.95501.41%

成交量：5.24萬

成交額：356.59萬

市值：5.96億

市盈率：26.52

高：68.56

開：68.18

低：67.83

收：67.51

52周最高：74.35

52周最低：45.80

股本：870.03萬

流通股本：870.03萬

量比：0.69

換手率：0.60%

股息：0.34

股息率：0.50%

每股收益(TTM):2.58

每股收益(LYR):-0.1280

淨資產收益率：42.40%

總資產收益率：0.26%

市淨率：1.39

市盈率(LYR):-534.82

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

松江奇蹟：一家中國藥企的「體系化出海」豪賭｜未來企業調研行

华夏时报网

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/XPH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XPH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","market":"US","secType":"STK","nameCN":"SPDR S&P Pharmaceuticals ETF","latestPrice":68.465,"timestamp":1789403335106,"preClose":67.51,"halted":0,"volume":52392,"delay":0,"changeRate":0.014146052436676021,"floatShares":8700270,"shares":8700270,"eps":2.581957,"marketStatus":"交易中","change":0.955,"latestTime":"09-14 12:31:40 EDT","open":68.18,"high":68.555,"low":67.83,"amount":3565896.4452000004,"amplitude":0.010739,"askPrice":68.53,"askSize":1100,"bidPrice":68.37,"bidSize":600,"shortable":3,"etf":1,"ttmEps":2.581957,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":67.51,"sharesOutstanding":5750270,"nav":67.590759,"aum":588057851.34,"dividendRate":0.004966,"bidAskSpread":0.001415,"postHourTrading":{"tag":"盘后","latestPrice":68.029,"preClose":67.51,"latestTime":"19:30 EDT","volume":519,"amount":35299.256,"timestamp":1789169406274,"change":0.519,"changeRate":0.007688,"amplitude":0.007688},"volumeRatio":0.687837,"impliedVol":0.2051,"impliedVolPercentile":0.9203},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XPH\",,,,,undefined,":{"symbol":"XPH","floatShares":8700270,"roa":"0.26%","roe":"42.40%","lyrEps":-0.128016,"volumeRatio":0.687837,"shares":8700270,"dividePrice":0.34,"high":68.555,"amplitude":0.010739,"preClose":67.51,"low":67.83,"week52Low":45.8,"pbRate":"1.39","psRate":"271.89","week52High":74.345,"institutionHeld":0,"latestPrice":68.465,"committee":-0.294118,"eps":2.581957,"divideRate":0.004966,"volume":52392,"delay":0,"ttmEps":2.581957,"open":68.18,"prevYearClose":56.01,"prevWeekClose":67.51,"prevMonthClose":70.62,"prevQuarterClose":66.27,"fiveDayClose":70.93,"twentyDayClose":70.98,"sixtyDayClose":60.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XPH\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XPH","amount":0.059045,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XPH","amount":0.060954,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XPH","amount":0.113024,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XPH","amount":0.102634,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XPH","amount":0.095872,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Pharmaceuticals ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XPH\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.059917,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.091273,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.026956,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.085023,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.07227,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XPH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XPH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666503466","title":"松江奇蹟：一家中國藥企的「體系化出海」豪賭 ｜ 未來企業調研行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666503466","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666503466?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 12:14","pubTimestamp":1789186482,"startTime":"0","endTime":"0","summary":"编者按：9月的一天，《华夏时报》未来企业竞争力调研团队来到位于上海松江的复宏汉霖全球生产基地——中国生物制药版图上，一处正在悄悄改写规则的所在。这家中国生物药企拒绝只卖“青苗”，而是试图用生物类似药的现金流，搭建从临床、报批到商业化的全球闭环。但真正的考验在于：创新药管线能否在专利悬崖窗口期兑现为第二增长曲线。上海松江，文俊路618弄。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872706781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872706781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731782.SGD","LU2272731865.HKD","LU2322448957.HKD","PPH","LU2322448791.USD","IBB","BCG","BK4135","BK4588","BK4585","IE00B5TLWC47.USD","LU1992135399.USD","LU1992135472.HKD","LU2473716301.USD","XPH","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0096","BK0188","BK1515","BK4585","LU2272731782.SGD","XPH","BK0196","BK1593","IBB","LU1992135399.USD","BK4588","BK0187","LU2322448791.USD","BK1191","LU2272731865.HKD","LU2322448957.HKD","BK0060","BK0012","LU2272731600.USD","PPH","BK0183","LU2473716301.USD","600196","IE00B5TLWC47.USD","BK0028","LU1992135472.HKD","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","06978","LU2322448791.USD","HK0000320264.USD","BK4588","LU2272731782.SGD","XPH","LU2473716301.USD","PPH","BK1574","IE00B5TLWC47.USD","HK0000320223.HKD","MEDX","LU2272731600.USD","IBB","LU2322448957.HKD","02696","LU1992135472.HKD","HK0000165453.HKD","HK0000306701.USD","LNGR","HK0000306685.HKD","159992","LU1992135399.USD","LU2272731865.HKD","IBBQ","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":6,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/XPH\",params:#limit:6,delay:false,,,undefined,":[]}}